

## POUŽITÁ LITERATURA

1. ABC symposium 1996 Solnohrad. Allergy. 1996;54 Suppl 49:103–199.
2. Abrahasson TR, et al. Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial. J Alerg Clin Immunol. 2007;119(5):1174–1180.
3. Baker BS. The role of microorganisms in atopic dermatitis. Clin Exp Immunol. 2006;144:1–9.
4. Barnes MJ, et al. Regulatory T cells reinforce intestinal homeostasis. Immunity. 2009;31(3):401–411.
5. Bartůňková J. Bakteriální imunomodulátory. Causa subita. 2006;6:384–386.
6. Bednář M, et al. Lékařská mikrobiologie. Praha: Marvil; 1996.
7. Belkaid Y, et al. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121–141.
8. Bennet R, et al. Development of the faecal anaerobic microflora after caesarean section and treatment with antibiotics in newborn infants. Infection. 1987;15(5):332–336.
9. Benno E, et al. Development of intestinal microflora in humans et animals: Bifidobacteria and Microflora. 1986;5:13–25.
10. Björkstén B. Karolinska Institutet: Probiotics; Facts, Fiction and Future, NASPGHAN San Diego 2008.
11. Bronský J. Využití probiotik v pediatrii. Lékařské listy. 2008.
12. Brouwer ML, Wolt-Pomplien, SA, Dubois, AE, et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. Clin Exp Allergy. 2006, 36, 899–906.
13. Burrows B. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med. 1989;320(5):271–277.
14. Bystroň J. Imunomodulace u recidivujících infekcí dýchacích cest. Klin Farmakol. 2005;19:235–238.
15. Bystroň J. Využití bakteriálních lyzátů v klinické praxi. Pediatr Prax. 2011;12(6):398–404.
16. Calder PC. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res. 2008;52:885–897.
17. Codex alimentarius comission. Joint FAO/WHO Food standarts programme. Codex commitee for specially dietary uses. July 2002, CX/NFSDU02/2.
18. Cukrowska B, Lodianová-Žádníková R, Enders C, et al. Specific proliferative and antibody responses of premature infants to intestinal colonization with non-pathogenic probiotic E. coli strain Nissle 1917. Scand J Immunol. 2002;55:204–209.
19. Cunningham-Rundles S, McNeeley DF, Moon A. Mechanisms of nutrient modulation of the immune response. J Allergy Clin Immunol. 2005;115:1119–1128.
20. Čadová L. Nové trendy v používání probiotik. Pediatr. prax. 2012; 13(1):60–62.
21. Červenková D, Kliment M, Ketyš P. Probiotiká a atopická dermatitiída. In: Kuchta M, Pružinec P. Probiotiká, ich miesto a využitie v medicíne. Bratislava: Bonus CCS; 2006. p. 98–106.
22. Dai D, Walker WH. Protective nutrients and bacterial colonization in the premature human gut. Adv Pediatr. 1999;46:353–382.
23. Damsgaard CT, Lauritzen L, Kjaer TM, et al. Fish oil supplementation modulates immune function in healthy infants. J Nutr. 2007;137:1031–1036.
24. Deshpande G, Rao S, Patole S, Bulsara M. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics. 2010;125(5):921–30.
25. Dunstan JA, Hale J, Breckler L, et al. Atopic dermatitis in young children is associated with impaired interleukin-10 and interferon  $\gamma$  responses to allergens, vaccines and colonizing skin and gut bacteria. Clin Exp Allergy. 2005;35:1309–1317.

26. Enck P, et al. The effects of maturation on the colonic microflora in infancy and childhood. *Gastroenterol Res Pract.* 2009;1–7.
27. Eyles JE. Therapeutic use of molecules that mimic pathogen danger signals. *Endocr Metab Immune Disord Drug Targets.* 2007;7:177–186.
28. Ezendam J. Probiotics: immunomodulation and evaluation of safety and efficacy. *Nutrition Rev.* 2006;64(1):1–14.
29. Favier CF, et al. Molecular monitoring of succession of bacterial communities in human neonates. *Appl Environ Microbiol.* 2002;68:219–226.
30. Fernandes CF, Shahani KM, Amer MA. Therapeutic role of dietary lactobacilli and lactobacillic fermented dairy products. *FEMS Microbiol. Rev.* 1987;46:343–356.
31. Feleszko W, et al. Probiotic-induced suppression of allergic sensitization and airway inflammation is associated with an increase of T regulatory-dependent mechanisms in a murine model of asthma. *Clin Exp Allergy.* 2007;37(4):498–505.
32. Frič P. Probiotika a prebiotika – renesance terapeutického principu. I. Teorie a experimentální doklady. *Postgrad Med.* 2005;7:472–477.
33. Frič P. Probiotika, prebiotika a atopie. *Pediatr Prax.* 2008;9(1):46–50.
34. Frühauf P, Fuchs M, Polášková S, Vernerová E, Zlatohlávková B. Alergie kojeneckého věku, Nestlé Nutrition. Olomouc: Solen; 2006. p. 3–59.
35. Frühauf P. Racionální užití probiotik v pediatrii. Zdroj [www.edukafarm.cz](http://www.edukafarm.cz).
36. Fuchs M. Potravinová alergie. *Postgrad Med.* 2004;5:546–549.
37. Fuchs M. Potravinové alergie. *Pediatrie po promoci.* 2004;1:26–35.
38. Fukushima Y, et al. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. *Int J Food Microbiol.* 1998;42:39–44.
39. Gibson GR, et al. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. *J Nutr.* 1995;125:1401–1412.
40. Gotoff SP. Neonatal immunity. *J Pediatr.* 1974;85:149.
41. Grönlund G, et al. Fecal microflora in healthy infants born by differnt methods of delivery: permanent changes in intestinal flora after cesarean delivery. *J Pediatr Gastroenterol Nutr.* 1999;28:19–25.
42. Grubb R, Conway PL, et al., editors. *Lactobacilli: Fact and fiction, in the regulatory and protective role of the normal microflora.* Hampshire: Macmillen Press; 1989. p. 263–281.
43. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis and therapeutic opportunities. *Inflamm Bowel Dis.* 2006;12:3–9.
44. He F, Morita, H, Hashimoto, H, et al. Intestinal Bifidobacterium species induce varying cytokine production. *J Allergy Clin Immunol.* 2002;109:1035–1036.
45. Helgeland L, et al. Development and function of intestinal B and T cells. *Microb Ecol Health Dis.* 2000;11:110–127.
46. Hlavatá A, et al. Environmentalne rizikové faktory vývoja atopie u detí. *Čes Slov Pediat.* 2007;62(12):674–683.
47. Hoffjan S, et al. Genetic variation in immunoregulatory pathways and atopic phenotypes in infancy. *J Allergy Clin Immunol.* 2004;113:511–518.
48. Holeček V, Liška J. Alergie a volné radikály. *Vox paediatricae.* 2016;3:16–17.
49. Holgate ST. The sentinel role of the airway epithelium in asthma pathogenesis. *Immunol Rev.* 2011;242:205–219.
50. Holt PG, Jones CA. The development of the immune system during pregnancy and early life. *Allergy.* 2000;55(8):688–697.
51. Hrdý J, et al. *Vox Ped.* 2007;8(7):32.
52. Chen K, Huang J, Gong W, et al. Toll-like receptors in inflammation, infection and cancer. *Int Immunopharmacol.* 2007;7:1271–1285.
53. Ismail IH, et al. Probiotic effects in allergic disease. *J Paediatr Child health.* 2013;49(9):709–715.
54. Isolauri E, Arvola T, Sutas Y, et al. Probiotics in the management of atopic eczema. *Clin Exp Allergy.* 2000;30:1604–1610.
55. Isolauri E, et el. Probiotics: effects of immunity. *Am J Clin Nutr.* 2001;73 suppl 2:444–450.

56. Isolauri, E, Majamaa, H, Arvola, T, et al. Lactobacillus casei strain LGG reverses increased intestinal permeability induced by cow milk in suckling rats. *Gastroenterology*. 1993;105:1643–1650.
57. Isolauri E. Dietary modification of atopic disease: use of probiotics in atopic dermatitis. *Curr Allergy Asthma Rep*. 2004;4:270–275.
58. Jeřábková M. Střevní mikroflóra – součást slizničního imunitního systému. *TIGIS*. 2008;12:23–44.
59. Jeseňák M, et al. Diagnostický algoritmus potravinové alergie v dětském věku. *Čes Ped*. 2008;5:272–282.
60. Jones CA. Does atopic disease start in foetal life? *Allergy*. 2000;55:2–10.
61. Kalliomäki M, et al. Distinct patterns of neonatal gut microflora in infants whom atopy was and was not developing. *J Allergy Clin Immunol*. 2001;107:129–134.
62. Kalliomäki M, et al. Early differences in fecal microbiota composition in children may predict overweight. *Am J Clin Nutr*. 2008;87:534–538.
63. Kalliomäki M, et al. Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of allergic diseases by probiotics. *J Nutr*. 2010;140(3):713S–21S.
64. Kalliomäki M, et al. Transforming growth factor-beta in breast milk: a potential regulator of atopic disease at an early age. *J Allergy Clin Immunol*. 1999;104:1251–1257.
65. Kalliomäki M, Salminen S, Arvilommi H, et al. Probiotics in primary prevention of atopic disease. *Lancet*. 2001;357:1076–1079.
66. Kalliomäki M, Salminen S, Poussa T, et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. *Lancet*. 2003;361:1869–1871.
67. Kayserová J. Autoreferát doktorské disertační práce 2013. Ústav imunologie 2. LF UK Praha.
68. Kirjavainen PV, Apostolou E, Arvola T, et al. Characterizing the composition of intestinal microflora as a prospective treatment target in infant allergic disease. *FEMS Immunol Med Microbiol*. 2001;32:1–7.
69. Kirjavainen PV, Arvola T, Salminen SJ, et al. Aberrant composition of gut microbiota of allergic infants: a target of bifidobacterial therapy at weaning? *Gut*. 2002;51:51–55.
70. Kjellman C, Olofsson SP, Hansson O, et al. Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. *Int J Cancer*. 2000;20:89(3):251–8.
71. a) Kjellman C, Sjögren HO, Salford LG, et al. HERV-F (XA34) is a full-length human endogenous retrovirus expressed in placental and fetal tissues. *Gene*. 1999;239(1):99–107./  
b) Kjellman C, Sjögren HO, Widegren B. HERV-F, a new group of human endogenous retrovirus sequences. *J Gen Virol*. 1999;80(9):2383–92.
73. Kniker TW. Delayed and non-IgE mediated reactions. In: Frieri M, Kettelhut B. *Food hypersensitivity and adverse reactions*. Marcel Dekker, Inc.; 1999. p. 165–193.
74. Krejsek J. Nutrice, probiotika a imunitní systém II. část: nutrice, přirozená slizniční mikroflóra a individuální imunitní reaktivita. *Pediatr Prax*. 2007;3:156–162.
75. Kudsk KA. Current aspects of mucosal immunology and its influence by nutrition. *Am J Surgery*. 2002;183:390–398.
76. Kukkonen K, et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. *J Allergy Clin Immunol*. 2007;119(1):192–198.
77. Laitinen K, Kalliomäki M, Poussa T, et al. Evaluation of diet and growth in children with and without atopic eczema: follow-up study from birth to 4 years. *Br J Nutr*. 2005;94:565–574.
78. Lee JAB, Seto DBA, Bielary L. Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. *J Allergy Clin Immunol*. 2008;121:116–121.
79. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. *Nat Rev Immunol*. 2007;7(5):379–390.
80. Lilly DM, Stillwell RH. Probiotics growth-promoting factors produced by microorganisms, science. 1965;12;147(3659):747–8.

81. Lodinová-Žádníková R. Probiotika v pediatrii: Snížení rizika nosokomiálních infekcí perorálním osídlením probiotickým kmenem *E. coli* po narození a jeho vliv na frekvenci opakovaných infekcí a alergíí po 10 a 20 letech. *Alergie*. 2002;4:275–279.
82. Lodinova-Zadnikova R, Cukrowska B, Tlaskalova-Hogenova H. Oral administration of probiotic *Escherichia coli* after birth reduces frequency of allergies and repeated infections later in life (10 and 20 years). *Int Arch Allergy Immunol*. 2003;131:209–211.
83. Lodinova-Zadnikova R, Slavikova M, Tlaskalova-Hogenova H, et al. The antibody response in breast-fed and non-breast-fed infants after artificial colonization of the intestine with *E. coli* O83. *Pediatr Res*. 1991;29:31–39.
84. Lodinova-Zadnikova R, Tlaskalova-Hogenova H, Bartakova Z. The antibody response in infants after colonization of the intestine with *E. coli* O83. Artificial colonization used as prevention against nosocomial infections. *Adv Exp Med Biol*. 1991;310:329–333.
85. Lochman I, et al. Úskalí v laboratorní diagnostice alergických onemocnění. *Vox Pediatriae*. 2002;6:28–29.
86. Lukáš M. Prebiotika, probiotika a střevní mikroflora. *Interní med*. 2015;17(1):14–17.
87. Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. *J Allergy Clin Immunol*. 1997;99:179–185.
88. Malmgren R, et al. Lowered glutathione-peroxidase activity in asthmatic patients with food and aspirin intolerance. *Allergy*. 1986;41:43–45.
89. Marques AH, et al. The influence of maternal prenatal and early childhood nutrition and maternal prenatal stress on off spring immune system development and neurodevelopmental disorders. *Front Neurosci*. 2013;7:120.
90. Martin E, et al. Human milk is a source of lactic acid bacteria for the infant gut. *J Pediatr*. 2003;14:754–758.
91. Matsamura T, et al. Studies on congenital sensitization. 1. Detection of food antigens and antibodies in the maternal serum, umbilical cord serum, the serum and the 1st voided urine of newborn infants, amniotic fluid and meconium. *Arerugi*. 1967;16(12):858–65.
92. Mebias RE. Organogenesis of lymphoid tissues. *Nat Rev Immunol*. 2003;3(4):292–303.
93. Miettinen M, et al. Lactobacilli and streptococci induce interleukin-12, IL-18, and gamma interferon production in human peripheral blood mononuclear cells. *Infect Immun*. 1998;66:6058–62.
94. Metchnikoff E. In: *The prolongation of life: Optimistic studies*, NY Pulman's Sons, 1908.
95. Miler I. Ontogeneze imunity plodu u novorozence. *Čes Pediat*. 1978;33(5):295–301.
96. Mísařovičová Z. Některé faktory humorální a celulární imunity u novorozenců. *Čes Pediat*. 1980;35(8):416–418.
97. Mocková A. Ovlivnění vývoje imunity v prenatálním a perinatálním období. *Pediatr Prax*. 2014;15(4):197–200.
98. NASPGHAN Nutrition Report Committee et al. Clinical efficacy of probiotics: review of the evidence with focus of children. NASPGHAN Nutrition Report Committee. *J Pediatr Gastroenterol Nutr*. 2006;43:550–557.
99. Neaville VA, et al. Developmental cytokine response profiles and the clinical and immunological expression of atopy during the first year of life. *J Allergy Clin Immunol*. 2003;112:740–746.
100. Nevoral J. Prebiotika a probiotika v pediatrii. *Pediatr Prax*. 2012;13(3):167–173.
101. Nevoral J. Probiotika a prebiotika. *Medical Tribune*. 2008;13.
102. Nissle A. Über die Grundlagen einer neuen ursachlichen Bekämpfung der pathologischen Darmflora. *Dtsch Med Wochenschr*. 1916;42:1181–1184.
103. Niers LE, Timmerman HM, Rijkers GT, et al. Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines. *Clin Exp Allergy*. 2005;35:1481–1489.
104. Nováková D. Riziko rozvoje alergických onemocnění v dětském věku – role časné výživy pro ustanovení vyvážené slizniční imunity zažívacího traktu. *Čes Pediat*. 2009;7–8.
105. Novarr MC. The microflora hypothesis of allergic diseases. *Clin Exp Allergy*. 2005;35(12):1511–1520.
106. Ogden NS, Bielory, L. Probiotics: a complementary approach in the treatment and prevention of pediatric atopic disease. *Curr Opin Allergy Clin Immunol*. 2005;5:179–184.

107. Okada H, et al. The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. *Clin Exp Immunol.* 2010;160(1):1–9.
108. Olivares M, et al. Antimicrobial potential of four *Lactobacillus* strains isolated from breast milk. *J Appl Microbiol.* 2006;10:72–79.
109. Orrhage K, et al. Factors controlling the bacterial colonization of the intestine in breastfed infants. *Acta Paediatr.* 1999;88:47–57.
110. Ouwehand AC, Isolauri E, He F, et al. Differences in *Bifidobacterium* flora composition in allergic and healthy infants. *J Allergy Clin Immunol.* 2001;108:144–145.
111. Parker RB. Probiotics, the other half of the antibiotic story. *Anim. Nutr. Health.* 1974;29:4–8.
112. Parracho H, et al. Probiotics and prebiotics in infant nutrition. *Proc Nutr Soc.* 2007;66(3):405–411.
113. Pařízková E. Imunologická nezralost novorozence a kojence. *Alergie, Supplementum.* 2002;3:14.
114. Pelech T, Frič P, Fixa B, et al. Srovnání Mutafli oru a mesalazinu v udržovací léčbě neaktivní idiopatické proktokolitidy. *Prakt Lékař.* 1998.
115. Perdigón G, et al. Study of the possible mechanisms involved in the mucosal immune system activation by lactic acid bacteria. *J Dairy Sci.* 1999;82(6):1108–1114.
116. Perdigón G, et al. The oral administration of lactic acid bacteria increase the mucosal intestinal immunity in response to enteropathogens. *J Food Protection.* 1990;53:404–410.
117. Perrier C, et al. Gut permeability and food allergies. *Clin Exp Allergy.* 2010;41:20–28.
118. Pessi T, Sutas Y, Hurme M. Interleukin-10 generation in atopic children following oral *Lactobacillus rhamnosus* GG. *Clin Exp Allergy.* 2000;30:1804–1808.
119. Peters JL, et al. Prenatal negative life events increases cord blood IgE: interactions with dust mite allergen and maternal atopy. *Allergy.* 2012;67(4):545–551.
120. Petruš P, Špičák, V. a kol. Vývoj alergie v průběhu života. *Alergologie.* Galén; 2004. p. 149–151.
121. Platts-Mills TA, et al. Is the hygiene hypothesis still a viable explanation for the increased prevalence of asthma? *Allergy.* 2005;79(60):25–31.
122. Platts-Mills TA. The role of allergens in the induction of asthma. *Curr Allergy Asthma Rep.* 2002;2(2):75–180.
123. Platts-Mills TAE. Indoor alergens. In: Adkinson NFJR, Yunginger JW, Busse WW, et al. Middleton's Allergy Principles & Practise. Philadelphia, Pensylvania: Mosby; 2003.
124. Pozler O. Střevní mikroflora. Sympozium o morfologii střeva. Staré Splavy, 2004;4:3–4 Abstr.
125. Prescott SL, Dunstan JA, Hale J, et al. Clinical effects of probiotics are associated with increased interferon-gamma response in very young children with atopic dermatitis. *Clin Exp Allergy.* 2005;35:1557–1564.
126. Pruzzo C. Short chain fatty acids, menaquinones and ubiquinones and their effects on the host. *Microb Ecol Health Dis.* 2009;12:209–215.
127. Rautava S, Kalliomäki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. *J Allergy Clin Immunol.* 2002;109:119–121.
128. Rautava S, Ruuskanen O, Ouwehand A, et al. The hygiene hypothesis of atopic disease – an extended version. *J Pediatr Gastroenterol Nutr.* 2004;38:378–388.
129. Rembacken BJ, et al. Non-pathogenic *Escherichia coli* versus mesalazine for the treatment of ulcerative colitis: a randomised trial. *Lancet.* 1999;354:635–639.
130. Romagnini E, et al. Increased numbers of Th2-like CD4+ T cells in target organs and in the allergen-specific repertoire of allergic patients. Possible role of IL-4 produced by non-T cells. *Int. Arch. Allergy Appl Immunol.* 1991;94(1–4):133–136.
131. Romangan S. The role of lymphocytes in allergic disease. *J Allergy Clin Immunol.* 1999;105:399–408.
132. Rosenfeldt V, Benfeldt E, Nielsen SD, et al. Effect of probiotic *Lactobacillus* strains in children with atopic dermatitis. *J Allergy Clin Immunol.* 2003;111:389–395.
133. Rosenfeldt V, Benfeldt E, Valerius NH, et al. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. *J Pediatr.* 2004;145, 612–616.

134. Saavedra JM, et al. Use of probiotics in pediatrics: rationale, mechanismus of action and practical aspects. *Nutrition in Clinical Practice*. 2007; 22, 351–365.
135. Salvatore S, Keymolen K, Hauser B, Vandenplas Y. Intervention during pregnancy and allergic disease in the offspring. *Pediatr Allergy Immunol*. 2005;16:558–566.
136. Sartor RB. Therapeutic correction of bacterial dysbiosis discovered by molecular techniques. *Proc Natl Acad Sci. USA*. 2008;105(43):16413–16414.
137. Servin A, Chauvire G, Polter M, Liévin-Le Moal V, Gastebois B. *Lactobacillus fermentum* strain and uses thereof. 2006; US Patent 0,134,220.
138. Schmidt-Weber CB, Blaser K. New insights into the mechanisms of allergen-specific immunotherapy. *Curr Opin Allergy Clin Immunol*. 2005;5:525–530.
139. Sistek D, Kelly R, Wickens K, et al. Is the effect of probiotics on atopic dermatitis confined to food sensitized children? *Clin Exp Allergy*. 2006;36:629–633.
140. Sjogren YM, et al. Influence of early gut microbiota on the maturation of childhood mucosal and systemic immune responses. *Clin Exp Allergy*. 2009;39(12):1842–1851.
141. Smetana K, et al. A further contribution to the demonstration of RNA and nucleoli of blood cells in smear preparations. *Folia haematologica*. 1969;91(4):381–394.
142. Smits HH, Engering A, van der Kleij, et al. Selective probiotic bacteria induce IL-10-producing regulatory T-cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. *J Allergy Clin Immunol*. 2005;115:1260–1267.
143. Sochorová V. Podávání a účinky aplikace Colinfantu u nedonošených dětí. *Vox.Ped.* 2003;9 (7):3, 26–27.
144. Spilková J. Echinacea sp. – obsahové látky a léčebné využití. *Prakt. lékáren*. 2006;2:89–92.
145. Strachan DP. Hay fever, hygiene and household size. *BMJ*. 1989;299:1259–1260.
146. Strimas JH, et al. Significance of IgE level in amniotic fluid and cord blad for the prediction of allergy. *Ann Allergy*. 1988;61:133–136.
147. Sudo N, et al. The requirement of intestinal bacterial flora for the development of an IgE system fully susceptible to oral tolerance induction. *J Immunol*. 1997;159:1739–1745.
148. Sýkora J, et al. Effects of a specialy designed fermented milk product containing probiotic *Lactobacillus casei* DN-114 001 and the eradication of *H. pylori* in children: a prospective randomized double-blind study. *J Clin Gastroenterology*. 2005;39(8):692–698.
149. Szajewska H, et al. Probiotics in gastrointestinal diseases in children. Hard and not-so hard evidence of efficacy. *J Pediatr Gastroenterology Nutrition*. 2006;42:454–475.
150. Šedivá A. Genetika alergie. *Alergie*. 2004;4.
151. Špičák V. Hygienická hypotéza-možnost nebo dogma. *Alergie*. 2005;3:180–183.
152. Šrůtková D. Charakterizace a využití složek střevní mikroflóry. Mikrobiologický ústav AV ČR, Dizertační práce 2015.
153. Thomas DW, Greer FR; American Academy of Pediatrics Committee on Nutrition; American Academy of Pediatrics Section on Gastroenterology, Hepatology, and Nutrition. Probiotics and prebiotics in pediatrics. *Pediatrics*. 2010;126(6):1217–31.
154. Thon V. Imunologické principy bezpečného očkování dětí. *Pediatr Prax*. 2010;11(6):354–357.
155. Thon V. Intestinální mikroflóra v raném dětství – úloha při rozvoji infekčních a alergických chorob. *Pediatr Prax*. 2011;12(4):252–256.
156. Tláskal P. Využití probiotik v pediatrii. *Pediatr Prax*. 2008;9(5):288–292.
157. Tlaskalová H, Městecký J. Účast slizničního imunitního systému a komensálních bakterií v alergii. *Alergie*. 2012;2:124–133.
158. Tlaskalová-Hogenová H, et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. *Immunol Lett*. 2004;93(2–3):97–108.
159. Tlaskalová-Hogenová H, Štěpánková R, Tučková L, Farre MA, Funda DP, Verdu EF, et al. Autoimmunity, immunodeficiency and mucosal infections: chronic intestinal inflammation as a sensitive indicator of immunoregulatory defects in response to normal luminal microflora. *Folia Microbiol*. 1998;43:545–50.
160. Tlaskalová-Hogenová H, Tučková L, Lodinová-Zádníková R, Štěpánková R, Cukrowska B, Funda DP, et al. Mucosal immunity: its role in defense and allergy. *Int Arch Allergy Immunol*. 2002;128:77–89.

161. Tlaskalová-Hogenová H. Imunita na sliznicích. Forum imunologie. 1994;1.
162. Tláskalová-Hogenová, H. Střevní imunitní systém a komensální bakterie. Medical Tribune. 2008;11.
163. Toh ZQ, et al. Probiotic therapy as a novel approach for allergic disease. Front Pharmacol. 2012;3:171.
164. Tomášová H, et al. Koncentrace eosinofilního kationického proteinu v séru donošených novorozenců. Neonatologické listy. 2000;4(6).
165. Turnbaugh P. The human microbiome project. Nature. 2007;449:804–810.
166. Uksila J, et al. Development of natural killer cell function in the human fetus. J Immunol. 1983;130(1):153–156.
167. Vandebulcke L, et al. The innate immune system and its role in allergic disorders. Int Arch Allergy Immunol. 2005;139:159–165.
168. Vandenplas Y. Microorganism administered for the Benefit of the host. Facts and Myths. Pediatric Gastroenterology and Nutrition in Clinical Practice. New York: Marcel Dekker, Inc.; 2002.
169. Végh V, Végh T. Přehled doplňkové imunomodulace v pediatrii. Pediatr Prax. 2008;9(6):388–392.
170. Vernerová E. Potravinová alergie v dětském věku. Pediatr Prax. 2007;8(5):269–272.
171. Vernerová E. Slizniční imunita u dětí, možnosti imunomodulace a alergie. Pediatr Prax. 2008;9(3):164–168.
172. Vernerová E. Výživa a alergie. Pediatr Prax. 2007;3:168–172.
173. Viljanen M, et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy. 2005;60(4):494–500.
174. Viljanen M, Kuitunen M, Haahtela T, et al. Probiotic effects on faecal inflammatory markers and on faecal IgA in food allergic atopic eczema/dermatitis syndrome infants. Pediatr Allergy Immunol. 2005;16:65–71.
175. Walker WA, et al. Progress in the science of probiotics: from cellular microbiology and applied immunology to clinical nutrition. Eur J Nutr. 2006;45 Suppl 9:1–18.
176. Walker WA. Role of Nutrients and Bacterial Colonization in the Development of Intestinal Host Defense. J of Ped Gastroenterol and Nutr. 2000;30:S2–S7.
177. Weston S, Halbert A, Richmond P, et al. Effects of probiotics on atopic dermatitis: a randomized controlled trial. Arch Dis Child. 2005;90:892–897.
178. Wuthrich B. Food allergy, frequency of symptoms and of food allergens among 402 patients with food allergy. Allergologie. 1993;16:280–287.
179. Yasui H, et al. Detection of bifidobacterium strains that induce large quantities of IgA. Microb Ecol Health Dis. 1992;5:155–162.
180. Yazdanbakhsh M, et al. Allergy, parasites, and the hygiene hypothesis. Science. 2002;296:490–494.
181. Zavázal V. Alergické stavy a mechanismy jejich vzniku. Forum imunologie. 1994;6:223–226.
182. Zavázal V. Hladiny imunoglobulinů G, A, M, D a E v běžné dětské populaci. Čes Pediat. 1974;29(5):249–252.
183. Zbořil V. Fyziologie mikroflory trávicího ústrojí jako základ probiotické terapie. Postgraduální medicína. 2002;8:824–827.
184. Zbořil V. Probiotika v léčbě idiopatických střevních zánětů. Alergie. 2004;3:151–155.
185. Zieger RS. Development and prevention of allergic diseases in childhood. In: Middleton E, et al. editors. Allergy Principles and Practices. 4th ed. Vo. 11. 1993. p. 1137–1171.